In a recent scientific study, the scientists created lab mice showing mutation. The mutation was meant to protect them from developing the Alzheimer’s disease. The mutation resulted in lowering their amyloid-beta production. The amyloid-beta is a molecule that can cause plaque in the brain. The future endeavors of the research lie in the detection of the link between the current study with the mutation in humans.
The current research work finds its way in the journal named Nature Communications. It marks its entry there on May 04, 2018. The study involves the researchers from the RIKEN Center for the Brain Science in Japan. The team made the use of the gene editing tool to bring about a mutation in the mice. The gene editing tool is known as the CRISPR technology. The mice were mutated for the App gene. The App gene is responsible associated with the formation of the amyloid-beta built up in the brain. According to the medical practitioners, the Alzheimer’s patients have amyloid-beta built up in their brain. If not addressed immediately it may interfere with the brain cell communication.
A press report states that there is a ray of hope that the mutation of the App gene will reduce the production of the amyloid-beta plaque in the brain. The mice were specially designed to possess the rodent version of the Alzheimer’s. They were observed at the six months of age. The study involved both male and female mice. Also, it includes the mice that carry the genetic mutation, and some were without the modifications.
Results of the current study indicate that the mice with the gene mutation received protection from the Alzheimer’s disease. It exhibits reduced accumulation of the amyloid-beta.
The research looks forward to the gene editing as a valuable measure in the Alzheimer’s disease study. The gene editing may also find its applications in the research on other diseases.